Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199906 | 0.85 | HTT (0.58) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL31595897 | 0.85 | HTT (0.58) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL28342438 | 0.83 | HTT (0.56) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27672403 | 0.83 | HTT (0.56) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL12386818 | 0.82 | HTT (0.63) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL8617215 | 0.82 | NPC1 (0.46) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL28761503 | 0.82 | HTT (0.63) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL10847357 | 0.82 | AR (0.51) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL11694952 | 0.82 | NPC1 (0.63) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL11109000 | 0.82 | HTT (0.47) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| EP-2258366-B1 | Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | KIRIN PHARMA KK (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8324245-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| CN-102574804-A | Quinolinyloxyphenylsulfonamides | MAX PLANCK GESELLSCHAFT | 2012-07-11 | — | — | CN | disclosed |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2258366-A2 | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | Kirin Pharma Kabushiki Kaisha (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1411046-B1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN PHARMA KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-2088141-A2 | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | Kirin Pharma Kabushiki Kaisha (JP) | 2009-08-12 | — | — | EP | disclosed |
| US-7425564-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1411046-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-5814646-A | TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5624937-A | TREATMENT OF ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-4753940-A | PARASITICIDE, ANTHELMINTIC | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
| EP-0191474-A1 | Barbituric-acid derivatives | CIBA-GEIGY AG (CH) | 1986-08-20 | — | — | EP | disclosed |
| US-4425343-A | Benzoazine ether or thioether linkage containing urea compounds, process for producing same and insecticides containing said compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1984-01-10 | — | — | US | disclosed |
| US-4376202-A | CHEMICAL INTERMEDIATES FOR INSECTICIDES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | KDM1A 722/4885MEN1 4701/4885KMT2A 876/4885 |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | NR1H2, NR1H3, NR1H4 | KDM1A 3506/4885MEN1 3975/4885KMT2A 2159/4885 |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | KDM1A 995/4885MEN1 3722/4885KMT2A 257/4885 |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | NR1H2, NR1H3, NR1H4 | KDM1A 2872/4885MEN1 4345/4885KMT2A 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.